SecBot SecBot

SYRE

Spyre Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001636282 Biotech & Drug Discovery
$99.37 −4.63 (−4.45%)
Nov 16 4:00 PM ET · prev $104.00
Market cap
$9.8B
Mid cap
Consensus
Buy
91% Buy or better · 23 analysts
Median target
$123.00
+24% · range $114.00–141.00
1 year
+307.9%
from $24.36 · Nov 17
30 days
+17.3%
from $84.72
52-week range
$23.47–109.00
−9% from high · low Nov 20
Avg volume 20D
974.9K
shares / day
Short interest
11.62M
≈12.2% of shares · −7.1%
Days to cover
12.7
at average volume
Insider net
−$16.9M
0 buyers · 4 sellers · since Aug 3
New fund stakes
6
Q2 2026 13F · 2 exits
Filing reports
30
analyzed by SecBot
SecBot read BEARISH 11 reports · 90 days
Balance 8 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 6/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $16.9M.

  • InstitutionsBULLISH

    Q2 2026: 49 added (6 new), 12 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $152.9M, Holocene Advisors $90.1M.

  • AnalystsBULLISH

    21 of 23 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.846 → −$0.998 over 90 days. 4 up, 7 down in 30 days.

  • Short sellersSTEADY

    Short interest −7.1% to 11.62M shares. 12.7 days to cover, ≈12.2% of shares.

  • TrendUPTREND

    8% above its 50-day average.

Who's buying

13F· Q2 2026
6
new positions
2
exits
$314.6M
in new stakes
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/ADD2,960,855$262.9M
GEODE CAPITAL MANAGEMENT, LLCADD2,562,265$239.3M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED2,330,098$206.9M
Capital World InvestorsDOUBLED2,315,553$205.6M
BANK OF AMERICA CORP /DE/ADD1,777,854$157.8M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW1,722,300$152.9M
GOLDMAN SACHS GROUP INCDOUBLED1,478,059$131.2M
Holocene Advisors, LPNEW1,015,170$90.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 91% rate it Buy or better
Strong Buy11Buy10Hold2Sell0Strong Sell0
12-month targets · 15 analysts

Price is below the lowest target. Median implies +24%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 4, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 4, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Oct 19, 2026BTIG
REITERATE
REITERATEBuy
Oct 12, 2026UBS
INITIATE
INITIATEBuy
Oct 1, 2026JP Morgan
INITIATE
INITIATEOverweight
Oct 1, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$16.9M
sold · 4 insiders
DateInsiderTypeValue
Oct 1, 2026
Burrows Scott L
Chief Financial Officer
Oct 1, 2026
EXERCISE$108.8K
Oct 1, 2026
Burrows Scott L
Chief Financial Officer
Oct 1, 2026
SELL$53.4K
Oct 1, 2026
Burrows Scott L
Chief Financial Officer
Oct 1, 2026
SELL$135.4K
Oct 1, 2026
Burrows Scott L
Chief Financial Officer
Oct 1, 2026
SELL$193.0K
Oct 1, 2026
Burrows Scott L
Chief Financial Officer
Oct 1, 2026
SELL$285.4K
Oct 1, 2026
Burrows Scott L
Chief Financial Officer
Oct 1, 2026
SELL$21.4K
Oct 1, 2026
King-Jones Heidy
See Remarks
Oct 1, 2026
SELL$35.7K
Oct 1, 2026
King-Jones Heidy
See Remarks
Oct 1, 2026
SELL$1.5M

Earnings setup

Estimates
−$1.00
EPS estimate, this quarter
−18%
estimate change, 90 days
4↑ 7↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.00-$1.91–-$0.50-16.4%$0.00
Next Q-$0.92-$1.10–-$0.67-10.3%$0.00
Current FY-$3.04-$3.95–-$2.52-6.9%$0.00
Next FY-$3.69-$4.55–-$2.36-4.8%$0.00

Washington

Corporate Lobbying

5 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
11,617,573
shares short
-7.1%
vs prior settlement
12.7
days to cover
≈12.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
9 drugs tracked · Drug pipeline →
Recent
Nov 10, 2026
Press release
Spyre Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to…
Nov 6, 2026
Press release
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology…
Nov 5, 2026
Earnings date
SYRE Q3 2026 Earnings Scheduled · 2026-11-05
Nov 3, 2026
Earnings
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three…
Oct 5, 2026
Offering
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology…

SecBot reports

30 filings · 6 press releases · 6 bullish · 11 bearish · 1 mixed · 12 neutral
All SYRE filing & press-release reports (36)